WO1997009036A3 - Improved pharmaceutical ion exchange resin composition - Google Patents

Improved pharmaceutical ion exchange resin composition Download PDF

Info

Publication number
WO1997009036A3
WO1997009036A3 PCT/GB1996/002156 GB9602156W WO9709036A3 WO 1997009036 A3 WO1997009036 A3 WO 1997009036A3 GB 9602156 W GB9602156 W GB 9602156W WO 9709036 A3 WO9709036 A3 WO 9709036A3
Authority
WO
WIPO (PCT)
Prior art keywords
ion exchange
exchange resin
resin composition
improved pharmaceutical
sugar
Prior art date
Application number
PCT/GB1996/002156
Other languages
French (fr)
Other versions
WO1997009036A2 (en
Inventor
Sandra Therese Antoi Malkowska
Derek Allan Prater
Stewart Thomas Leslie
Adrian Brown
Trevor John Knott
Original Assignee
Euro Celtique Sa
Sandra Therese Antoi Malkowska
Derek Allan Prater
Stewart Thomas Leslie
Adrian Brown
Trevor John Knott
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa, Sandra Therese Antoi Malkowska, Derek Allan Prater, Stewart Thomas Leslie, Adrian Brown, Trevor John Knott filed Critical Euro Celtique Sa
Priority to EP96928628A priority Critical patent/EP0847273B1/en
Priority to AT96928628T priority patent/ATE213152T1/en
Priority to US09/029,151 priority patent/US6077532A/en
Priority to AU68347/96A priority patent/AU6834796A/en
Priority to DE69619250T priority patent/DE69619250T2/en
Publication of WO1997009036A2 publication Critical patent/WO1997009036A2/en
Publication of WO1997009036A3 publication Critical patent/WO1997009036A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Abstract

A process is provided for preparing a granular pharmaceutical ion exchange resin composition that is readily dispersible in water by granulating an ion exchange resin, having a pharmacologically active ingredient bound thereto, with a particulate sugar or sugar alcohol. The process is characterised by the use of an aqueous solution of a sugar or sugar alcohol as a granulating medium.
PCT/GB1996/002156 1995-09-01 1996-09-02 Improved pharmaceutical ion exchange resin composition WO1997009036A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP96928628A EP0847273B1 (en) 1995-09-01 1996-09-02 Improved pharmaceutical ion exchange resin composition
AT96928628T ATE213152T1 (en) 1995-09-01 1996-09-02 IMPROVED DRUGS USING AN ION EXCHANGE RESIN
US09/029,151 US6077532A (en) 1995-09-01 1996-09-02 Pharmaceutical ion exchange resin composition
AU68347/96A AU6834796A (en) 1995-09-01 1996-09-02 Improved pharmaceutical ion exchange resin composition
DE69619250T DE69619250T2 (en) 1995-09-01 1996-09-02 IMPROVED MEDICINES WITH AN ION EXCHANGE RESIN

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9517883.6 1995-09-01
GBGB9517883.6A GB9517883D0 (en) 1995-09-01 1995-09-01 Improved pharmaceutical ion exchange resin composition

Publications (2)

Publication Number Publication Date
WO1997009036A2 WO1997009036A2 (en) 1997-03-13
WO1997009036A3 true WO1997009036A3 (en) 1997-04-24

Family

ID=10780065

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/002156 WO1997009036A2 (en) 1995-09-01 1996-09-02 Improved pharmaceutical ion exchange resin composition

Country Status (9)

Country Link
US (1) US6077532A (en)
EP (1) EP0847273B1 (en)
AT (1) ATE213152T1 (en)
AU (1) AU6834796A (en)
DE (1) DE69619250T2 (en)
ES (1) ES2170258T3 (en)
GB (1) GB9517883D0 (en)
PT (1) PT847273E (en)
WO (1) WO1997009036A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2288876A1 (en) * 1997-05-06 1998-11-12 Xiao Yu Wu Drug delivery system
WO1999032119A1 (en) * 1997-12-22 1999-07-01 Euro-Celtique, S.A. Opioid agonist/antagonist combinations
UA53774C2 (en) * 1997-12-22 2003-02-17 Еро-Селтік, С.А. Method of reducing abuse potential of an oral dosage form of opioid analgesic
US6221308B1 (en) * 1999-04-20 2001-04-24 Corning Incorporated Method of making fired bodies
HU229705B1 (en) * 2000-02-08 2014-05-28 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
NZ520975A (en) * 2000-02-24 2004-03-26 Upjohn Co New drug combinations containing a norepinephrine reuptake inhibitor and an antimuscarinic agent for treating nervous system disorders
ATE493130T1 (en) 2001-05-11 2011-01-15 Endo Pharmaceuticals Inc MEDICINAL FORM CONTAINING OPIOID AGAINST ABUSE
DE60230632D1 (en) * 2001-07-18 2009-02-12 Euro Celtique Sa PHARMACEUTICAL COMBINATIONS OF OXYCODONE AND NALOXONE
WO2003013433A2 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
ATE431738T1 (en) 2001-08-06 2009-06-15 Euro Celtique Sa OPIOID AGONIST FORMULATIONS WITH RELEASABLE AND SEQUESTRED ANTAGONIST
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
US20040067216A1 (en) * 2002-02-22 2004-04-08 Karki Shyam B. Hiv protease inhibitors supported on cation exchange resins for oral administration
EP2243471A1 (en) 2002-04-05 2010-10-27 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
DK1551372T3 (en) 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
AU2004270188B8 (en) * 2003-09-03 2010-04-29 Mallinckrodt Inc. Granular sustained release preparation and production thereof
US20050181050A1 (en) * 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
US20070232695A1 (en) * 2004-01-28 2007-10-04 Collegium Pharmaceutical, Inc. Gelled Periodontal Anesthetic Preparation
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
WO2006081518A2 (en) * 2005-01-28 2006-08-03 Collegium Pharmaceutical, Inc. Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
EP1702558A1 (en) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US8343546B2 (en) * 2005-09-13 2013-01-01 Coating Place, Inc. Ion exchange resin treated to control swelling
EP1834634A3 (en) * 2006-03-08 2007-10-03 Rentschler Pharma GmbH Pharmaceutical multiple-unit composition
CN101677963B (en) 2006-06-19 2012-05-30 奥尔制药公司 Pharmaceutical compositions
EP2120945A1 (en) * 2007-02-28 2009-11-25 Collegium Pharmaceutical, Inc. Antihistamine combination
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
DK2405915T3 (en) 2009-03-10 2019-02-11 Euro Celtique Sa PHARMACEUTICAL COMPOSITIONS WITH IMMEDIATE RELEASE INCLUDING OXYCODON AND NALOXON
KR20180037074A (en) 2013-07-23 2018-04-10 유로-셀티큐 에스.에이. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0200252A1 (en) * 1985-05-02 1986-12-10 Yamanouchi Europe B.V. Tablets comprising trimethoprim and a sulfonamide
EP0329977A2 (en) * 1988-02-25 1989-08-30 Xyrofin Oy A xylitol-based binding and diluting agent and a process for the production thereof
EP0368682A1 (en) * 1988-11-11 1990-05-16 Euroceltique S.A. Pharmaceutical ion exchange resin composition
WO1992016209A1 (en) * 1991-03-14 1992-10-01 Reanal Finomvegyszergyár Granules and veterinary compositions comprising a water-soluble complex of flumequine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3627583A (en) * 1969-04-29 1971-12-14 Sucrest Corp Direct compression vehicles
EP0328877A1 (en) * 1988-02-18 1989-08-23 Oerlikon-Contraves AG Projectile with a fragmenting shell

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0200252A1 (en) * 1985-05-02 1986-12-10 Yamanouchi Europe B.V. Tablets comprising trimethoprim and a sulfonamide
EP0329977A2 (en) * 1988-02-25 1989-08-30 Xyrofin Oy A xylitol-based binding and diluting agent and a process for the production thereof
EP0368682A1 (en) * 1988-11-11 1990-05-16 Euroceltique S.A. Pharmaceutical ion exchange resin composition
WO1992016209A1 (en) * 1991-03-14 1992-10-01 Reanal Finomvegyszergyár Granules and veterinary compositions comprising a water-soluble complex of flumequine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
P.H. LIST ET AL.: "hagers handbuch der pharmazeutischen praxis 4th edition volume 7 part A", 1971, SPRINGER VERLAG, BERLIN, HEIDELBERG, NEW YORK, XP002026431 *

Also Published As

Publication number Publication date
GB9517883D0 (en) 1995-11-01
ES2170258T3 (en) 2002-08-01
EP0847273B1 (en) 2002-02-13
US6077532A (en) 2000-06-20
WO1997009036A2 (en) 1997-03-13
ATE213152T1 (en) 2002-02-15
AU6834796A (en) 1997-03-27
DE69619250D1 (en) 2002-03-21
EP0847273A2 (en) 1998-06-17
PT847273E (en) 2002-06-28
DE69619250T2 (en) 2002-08-14

Similar Documents

Publication Publication Date Title
WO1997009036A3 (en) Improved pharmaceutical ion exchange resin composition
AU4453089A (en) Pharmaceutical ion exchange resin composition
AU2743995A (en) Solid microspheres for agriculturally active compounds and process for their production
CA2386690A1 (en) Pharmaceutical tramadol salts
AU8009998A (en) Method for producing orally administered, solid pharmaceutical products with controlled release of the active substance
CA2218048A1 (en) Water treatment tablet producing potable water
WO1999036099A8 (en) Sustained release compositions, process for producing the same and utilization thereof
AU764280C (en) Process for the preparation of pellets with a content of up to 90 wt. per cent of a pharmaceutical active ingredient
AU6020494A (en) Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
AU3091489A (en) Piperazine derivative or its salt, process for producing the same and pharmaceutical composition comprising the same as active ingredient
CA2097176A1 (en) New pharmaceutical formulations containing a pharmacologically active ionizable substance as well as process for the preparation thereof
IE900385L (en) Effervescent composition for oral rehydration
CA2153849A1 (en) Method for improving breeding activity of boars by using feed for the breeding boars
AU1811495A (en) Granular product or tablet containing an effervescent system and an active pharmaceutical substance, as well as a method for its preparation
AU1470195A (en) Nanoparticles containing an active substance and a ketalizedpolytartramidic acid, process for their preparation, and use thereof
CA2175664A1 (en) Method and composition for disinfecting and solidifying liquid waste
WO1997010810A3 (en) Pharmaceutical granules
AU692030B2 (en) Hydantoin derivatives, process for producing the same and herbicides comprising the same as active ingredients
CA2116631A1 (en) Process for the preparation of aqueous nicotinaldehyde
HUP9801439A3 (en) Use of beta-d-galactopyranosyl-d-xyloses for the preparation of compositions and solutions intended to the evaluation of intestinal lactase, and production process of the said compds.
EP0675905A1 (en) Oligosaccharides having biological activity and preparation of same from glycosaminoglycans.
MX9603342A (en) Piranes-4h-substituted.
HUP0004386A3 (en) Methylenebisphosphonic acid derivatives, process for producing them and medicaments containing the same as active agent
AU6367690A (en) Optically active thiazetoquinoline-3-carboxylic acid compound, method for preparation thereof, and a pharmaceutical composition comprising the same
AU5575594A (en) N-aryloxyacyl-n-phenyltetrahydrophthalamic acid derivative, process for producing the same, and herbicide containing the same as active ingredient

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996928628

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09029151

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1996928628

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 1996928628

Country of ref document: EP